Vpr protein
From Proteopedia
(Difference between revisions)
| (10 intermediate revisions not shown.) | |||
| Line 5: | Line 5: | ||
=== Vpr induce cell cycle arrest by recruits cellular targets for degradation<ref name='Wu2016'>PMID:27571178</ref> === | === Vpr induce cell cycle arrest by recruits cellular targets for degradation<ref name='Wu2016'>PMID:27571178</ref> === | ||
| - | One phenotype of Vpr expression is the induction of cell cycle arrest in G2 phase. This arrest executes by engaging of | + | One phenotype of Vpr expression is the induction of cell cycle arrest in G2 phase. This arrest executes by engaging of damage–binding protein 1 (DDB1) and CUL4A-associated factor 1 (DCAF1) to Vpr. DCAF1 is a substrate receptor of the Cullin4–RING E3 ubiquitin ligase (CRL4) of the host ubiquitin–proteasome-mediated protein degradation pathway. Mutations in Vpr that abolish its interaction with DCAF1, or silencing of DCAF1, eliminate cell-cycle arrest. The crystal structure of <scene name='75/750237/Vpr_ddb1_dcaf1_ung2/2'>DDB1–DCAF1–HIV-1–Vpr–uracil-DNA glycosylase (UNG2) complex</scene> elucidate the molecular mechanism in which Vpr inhibits UNG2 enzymatic activity and send it for degradation: |
| - | DCAF1 WD40 domain binds to Vpr by its N-terminus and α3 helix. In addition, DCAF1 is anchored into DDB1 by a helix-loop-helix motif. These motifs are commonly found in substrate receptor proteins that bind to DDB1. Finally, Vpr uses structural mimicry to DNA to engages UNG2. It interacts with UNG2 by residues in the hydrophobic cleft and an insert loop (residues 266–283), which mimics the phosphate backbone in the DNA. When interacts with DNA, UNG2 Leu272 residue uses to insert into the minor groove. The importance of Leu272 residue to UNG2-Vpr interaction was demonstrated by mutagenesis. Thus, Vpr recruite the CRL4–DCAF1 E3 ubiquitin ligase and targets cellular substrates for degradation. The reason for UNG2 degradation is not clear yet. However, their is a possibility that UNG2 exerts a negative effect on HIV-1 replication. | + | DCAF1 WD40 domain <scene name='75/750237/Dcaf1_vpr/1'>binds to Vpr</scene> by its N-terminus and α3 helix. In addition, <scene name='75/750237/Dcaf1_ddb1/1'>DCAF1 is anchored into DDB1</scene> by a helix-loop-helix motif. These motifs are commonly found in substrate receptor proteins that bind to DDB1. Finally, Vpr uses structural mimicry to DNA to <scene name='75/750237/Vpr_ung2/1'>engages UNG2</scene>. It interacts with UNG2 by residues in the hydrophobic cleft and an insert loop (residues 266–283), which mimics the phosphate backbone in the DNA. When interacts with DNA, UNG2 Leu272 residue uses to insert into the minor groove. The importance of Leu272 residue to UNG2-Vpr interaction was demonstrated by mutagenesis. Thus, Vpr recruite the CRL4–DCAF1 E3 ubiquitin ligase and targets cellular substrates for degradation. The reason for UNG2 degradation is not clear yet. However, their is a possibility that UNG2 exerts a negative effect on HIV-1 replication. |
== Disease == | == Disease == | ||
| Line 14: | Line 14: | ||
== Relevance == | == Relevance == | ||
| - | + | As of now (October 2017), the currently approved anti-HIV drugs target the Pol and Env encoded proteins. These drugs are effective in reducing viral replication. Thus, because of spontaneous mutations that occur during viral replication, drug resistance is evolve<ref>PMID:28681118</ref>. Understanding of Vpr structure and molecular mechanism may facilitate the design of HIV-1 antiviral therapy by its inhibition. Deletion of both ''vpr'' and ''vpx'' genes in SIV, which their protein products in SIV combine Vpr function in HIV-1, eliminate virus replication<ref name='Emerman1996'/>. The multiple significant functions that Vpr fills in HIV-1 replication makes it an attractive candidate for antiviral therapy<ref name='Gonzalez2017'/>. | |
| + | |||
| + | == Structural highlights<ref>PMID:12614620</ref> == | ||
| + | Vpr structure is characterized by three well-defined α-helices: 17–33, 38–50 and 56–77 surrounded by flexible N and C-terminal domains. Vpr has been determined by NMR in the presence of 30% TFE several times, in [[1esx]], [[1vpc]] and [[1ceu]] structures. TFE is known to stabilize secondary structures and to prevent interactions between hydrophobic cores. However, the result was <scene name='75/750237/Vpr/1'>less globular structure</scene> than what it could be in reality. So, another NMR solution of Vpr was determined in the presence 10–30% of CD3CN, a less hydrophobic solvent, and in pure water. <scene name='75/750237/Vpr/2'>In this structure</scene> ([[1m8l]]), the structure folding around a hydrophobic core was improved, and can explain the binding properties of Vpr. | ||
== Conservation == | == Conservation == | ||
| - | Vpr is <scene name='75/750237/Conservation/3'>highly conserved</scene> in HIV and simian immunodeficiency virus (SIV), similar retrovirus which infects non-human primates<ref name='Morellet2003'/>. In addition, all primate lentiviruses has Vpr gene whose protein product has highly conserved motifs. HIV-2 and SIVsm lentiviruses have additionally gene - | + | Vpr is <scene name='75/750237/Conservation/3'>highly conserved</scene> in HIV and simian immunodeficiency virus (SIV), similar retrovirus which infects non-human primates<ref name='Morellet2003'/>. In addition, all primate lentiviruses has Vpr gene whose protein product has highly conserved motifs. HIV-2 and SIVsm lentiviruses have additionally gene - ''vpx''. In these lentiviruses, Vpr and Vpx executes together the roles which HIV-1 Vpr perform. Vpr and Vpx has low conservation between them<ref name='Emerman1996'/>. However, Vpr and Vpx families of proteins use related structural regions to bind and recruit cellular targets to the E3 ligase complex for degradation by the proteasome<ref name='Wu2016'/>.<br/> |
[[Image:Consurf_key_small.gif|200px|right]] | [[Image:Consurf_key_small.gif|200px|right]] | ||
Current revision
| |||||||||||
3D Structures of Vpr protein
Updated on 10-April-2018
1m8l – Vpr - NMR - HIV-1
1esx - synthetic Vpr - NMR - HIV-1
5jk7 – Vpr + DDB1 + DCAF-1 + UNG2 – X-ray solution - HIV-1
1x9v – Dimeric structure of the Vpr C-terminal domain - NMR
1vpc - C-terminal domain of Vpr - NMR - HIV-1
1fi0 - Vpr residues 13-33 in micelles - NMR - HIV-1
1bde - NMR solution of Vpr peptides connected to cell cycle arrest and nuclear provirus transfer
5b56 - Importin subunit alpha-1 + Vpr C-terminal domain - crystallographic analysis
1kzs, 1kzt, 1kzv - Vpr residues 34-51 - NMR - HIV-1
1dsj - Vpr residues 50-75 - NMR - HIV-1
1ceu - Vpr N-terminal domain - NMR - HIV-1
1dsk - Vpr residues 59-86 - NMR - HIV-1
References
- ↑ 1.0 1.1 Morellet N, Bouaziz S, Petitjean P, Roques BP. NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol. 2003 Mar 14;327(1):215-27. PMID:12614620
- ↑ 2.0 2.1 Gonzalez ME. The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention. Int J Mol Sci. 2017 Jan 10;18(1). pii: ijms18010126. doi: 10.3390/ijms18010126. PMID:28075409 doi:http://dx.doi.org/10.3390/ijms18010126
- ↑ 3.0 3.1 Wu Y, Zhou X, Barnes CO, DeLucia M, Cohen AE, Gronenborn AM, Ahn J, Calero G. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nat Struct Mol Biol. 2016 Aug 29. doi: 10.1038/nsmb.3284. PMID:27571178 doi:http://dx.doi.org/10.1038/nsmb.3284
- ↑ 4.0 4.1 4.2 Emerman M. HIV-1, Vpr and the cell cycle. Curr Biol. 1996 Sep 1;6(9):1096-103. PMID:8805364
- ↑ Win NN, Ngwe H, Abe I, Morita H. Naturally occurring Vpr inhibitors from medicinal plants of Myanmar. J Nat Med. 2017 Oct;71(4):579-589. doi: 10.1007/s11418-017-1104-7. Epub 2017 Jul , 5. PMID:28681118 doi:http://dx.doi.org/10.1007/s11418-017-1104-7
- ↑ Morellet N, Bouaziz S, Petitjean P, Roques BP. NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol. 2003 Mar 14;327(1):215-27. PMID:12614620

